Monday, September 10, 2012

Health - Google News: Geron ends breast cancer study of Imetelstat - MarketWatch

Health - Google News
Google News
Geron ends breast cancer study of Imetelstat - MarketWatch
Sep 10th 2012, 12:05


Geron ends breast cancer study of Imetelstat
MarketWatch
By Melodie Warner Geron Corp. (NASDAQ:GERN) is discontinuing its Phase 2 study of imetelstat in metastatic HER2-negative breast cancer because the median progression-free survival was shorter than the comparison treatment. The biopharmaceutical company ...
Geron Provides Update on Imetelstat Clinical Development ProgramReuters
Geron drug fails breast cancer trial, shares sinkReuters UK
Implosion Day at Geron24/7 Wall St.
Benzinga
all 16 news articles »

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 comments:

Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More